Cargando…

Compassionate use of a novel β-lactam enhancer-based investigational antibiotic cefepime/zidebactam (WCK 5222) for the treatment of extensively-drug-resistant NDM-expressing Pseudomonas aeruginosa infection in an intra-abdominal infection-induced sepsis patient: a case report

Infections in critically-ill patients caused by extensively-drug-resistant (XDR)-Pseudomonas aeruginosa are challenging to manage due to paucity of effective treatment options. Cefepime/zidebactam, which is currently in global Phase 3 clinical development (Clinical Trials Identifier: NCT04979806, re...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dubey, Dilip, Roy, Manish, Shah, Tajamul H., Bano, Noor, Kulshrestha, Vidushi, Mitra, Sandeep, Sangwan, Pushpender, Dubey, Madhulika, Imran, Ali, Jain, Bhawna, Velmurugan, Aravind, Bakthavatchalam, Yamuna Devi, Veeraraghavan, Balaji
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Brief Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10324185/ https://www.ncbi.nlm.nih.gov/pubmed/37408075 http://dx.doi.org/10.1186/s12941-023-00606-x

Ejemplares similares

Cefepime-Zidebactam (WCK 5222) Activity Tested against Gram-negative Organisms Causing Bloodstream Infections Worldwide
por: Sader, Helio S, et al.
Publicado: (2017)

Molecular Characterization of WCK 5222 (Cefepime/Zidebactam)-Resistant Mutants Developed from a Carbapenem-Resistant Pseudomonas aeruginosa Clinical Isolate
por: Pan, Xiaolei, et al.
Publicado: (2022)

725. WCK 5222 (Cefepime/Zidebactam): An In Vitro Assessment of Activity Compared with Current Dual-Antibiotic Options Against Multidrug-Resistant Pseudomonas aeruginosa
por: Mullane, Elias M, et al.
Publicado: (2019)

1336. Assessment of the In Vivo Efficacy of WCK 5222 (Cefepime-Zidebactam) Against Carbapenems-Resistant Acinetobacter baumannii (CR-ACBN) in the Neutropenic Murine Thigh Infection Model
por: Abuhussain, Safa Almarzoky, et al.
Publicado: (2018)

2214. Comparison of Cefepime–Zidebactam (WCK 5222), Ceftazidime–Avibactam, and Ceftolozane–Tazobactam Tested Against Gram-Negative Organisms Causing Pneumonia in United States Hospitals in 2018
por: Sader, Helio S, et al.
Publicado: (2019)

675. Efficacy of Human-Simulated Bronchopulmonary Exposures of Cefepime and Zidebactam (WCK 5222) Against Multidrug-Resistant (MDR) Pseudomonas aeruginosa (PSA) in a Neutropenic Murine Pneumonia Model
por: Kidd, James M, et al.
Publicado: (2019)

1598. Antimicrobial Activity of the Novel β-Lactam Enhancer Combination Cefepime–Zidebactam (WCK-5222) Tested Against Gram-Negative Bacteria Isolated in United States Medical Centers from Patients with Bloodstream Infections
por: Castanheira, Mariana, et al.
Publicado: (2019)

A case series of melioidosis: An underdiagnosed infection()
por: Dubey, Dilip Kumar, et al.
Publicado: (2023)

685. An In Vitro Investigation of WCK 5222 (Cefepime/Zidebactam) and Currently Available Combination Antibiotic Regimens Against Enterobacteriaceae That Co-express Serine-β-Lactamase (SBL) and Metallo-β-Lactamase (MBL) Enzymes
por: Avery, Lindsay M, et al.
Publicado: (2019)

Case Commentary: Successful Use of Cefepime/Zidebactam (WCK 5222) as a Salvage Therapy for the Treatment of Disseminated Extensively Drug-Resistant New Delhi Metallo-β-Lactamase-Producing Pseudomonas aeruginosa Infection in an Adult Patient with Acute T-Cell Leukemia
por: Egge, Stephanie L., et al.
Publicado: (2023)

Activity of ertapenem/zidebactam (WCK 6777) against problem Enterobacterales
por: Mushtaq, Shazad, et al.
Publicado: (2022)

In Vitro Activity of Two Cefepime-Based Novel Combinations, Cefepime/Taniborbactam and Cefepime/Zidebactam, against Carbapenemase-Expressing Enterobacterales Collected in India
por: Bakthavatchalam, Yamuna Devi, et al.
Publicado: (2023)

In vitro activity of cefepime/zidebactam and cefepime/taniborbactam against aztreonam/avibactam-resistant NDM-like-producing Escherichia coli clinical isolates
por: Le Terrier, Christophe, et al.
Publicado: (2023)

In vivo efficacy of WCK 6777 (ertapenem/zidebactam) against carbapenemase-producing Klebsiella pneumoniae in the neutropenic murine pneumonia model
por: Gethers, Matthew, et al.
Publicado: (2022)

Activity of Cefepime-Zidebactam against Multidrug-Resistant (MDR) Gram-Negative Pathogens
por: Thomson, Kenneth S., et al.
Publicado: (2019)

Can fosfomycin be an alternative therapy for infections caused by E. coli harbouring dual resistance: NDM and four-amino acid insertion in PBP3?
por: Bakthavatchalam, Yamuna Devi, et al.
Publicado: (2023)

1244. Assessment of the In Vivo Activity of Human-Simulated Exposure of WCK 4282 (High Dose Cefepime [FEP]-Tazobactam [TZB]) against Enterobacterales (EB) and Pseudomonas aeruginosa (PA) in the Neutropenic Murine Thigh Infection Model
por: Gill, Christian M, et al.
Publicado: (2020)

2178. Resistance to Cefepime/Taniborbactam in NDM-1 -Are We Losing the Battle against MDROs?
por: Ono, Daisuke, et al.
Publicado: (2023)

Efficient Synthesis of Potential Impurities in Levonadifloxacin (WCK 771)
por: Kilbile, Jaydeo T., et al.
Publicado: (2021)

1245. In Vivo Efficacy of WCK 4282 (High Dose Cefepime [FEP]-Tazobactam [TZB]) Against β-Lactamase-Producing (BLP) Gram-Negative Bacteria in a Neutropenic Murine Pneumonia Model
por: Lasko, Maxwell J, et al.
Publicado: (2020)

Oral Antibiotics in Clinical Development for Community-Acquired Urinary Tract Infections
por: Veeraraghavan, Balaji, et al.
Publicado: (2021)

Zidebactam restores sulbactam susceptibility against carbapenem-resistant Acinetobacter baumannii isolates
por: Cedano, Jose, et al.
Publicado: (2022)

Electrocardiographic Effects of a Supratherapeutic Dose of WCK 2349, a Benzoquinolizine Fluoroquinolone
por: Mason, Jay W., et al.
Publicado: (2018)

Cefepime: Cefepime-induced encephalopathy: case report
Publicado: (2022)

HPLC Method for Determination of Enantiomeric Purity of a Novel Respiratory Fluoroquinolone: WCK 1152
por: Yeole, R. D., et al.
Publicado: (2008)

Letermovir for the compassionate therapeutic use of cytomegalovirus infection
por: Schubert, Lorenz, et al.
Publicado: (2020)

1228. Outcomes Associated with Empiric Cefepime or Meropenem for Bloodstream Infections Caused by Ceftriaxone-Resistant, Cefepime-Susceptible Escherichia coli and Klebsiella pneumoniae
por: Frescas, Brian E, et al.
Publicado: (2021)

Cefepime-induced encephalopathy
por: Kenzaka, Tsuneaki, et al.
Publicado: (2018)

Cefepime-Induced Encephalopathy
por: Keerty, Dinesh, et al.
Publicado: (2021)

Cefepime-Induced Neurotoxicity
por: Saini, Tanjot, et al.
Publicado: (2021)

Cefepime-Induced Delirium
por: Somoza-Cano, Francisco J, et al.
Publicado: (2021)

In Vitro Activity of Cefepime/AAI101 and Comparators against Cefepime Non-susceptible Enterobacteriaceae
por: Crandon, Jared L., et al.
Publicado: (2015)

Cefepime Therapy for Cefepime-Susceptible Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae Bacteremia
por: Wang, Ruibin, et al.
Publicado: (2016)

Compassionate Counterterrorism
por: Olaimy, Leena
Publicado: (2019)

Compassionate Care
por: Post, Stephen G., et al.
Publicado: (2012)

Compassionate Conversations
por: Gardner, Sharryn, et al.
Publicado: (2014)

2795. Cefepime Versus Meropenem for Infections Due to HECCcK-YeS-MAm Organisms with Cefepime MICs of 4-8 mCg/mL (S-DD)
por: Purdy, Andrew Scott, et al.
Publicado: (2023)

Laboratory Detection and Clinical Implication of Oxacillinase-48 like Carbapenemase: The Hidden Threat
por: Bakthavatchalam, Yamuna Devi, et al.
Publicado: (2016)

Cefepime-Resistant Pseudomonas aeruginosa
por: Akhabue, Ehimare, et al.
Publicado: (2011)

Some Pharmacodynamic Aspects of Cefepime
por: Elsayed, Mossad Gamaleddin Ahmed, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_55lhocj8rroq274ouialcgkkf6